McKesson Corporation (MCK)
NYSE: MCK · Real-Time Price · USD
760.57
+13.34 (1.79%)
At close: May 15, 2026, 4:00 PM EDT
765.00
+4.43 (0.58%)
After-hours: May 15, 2026, 7:48 PM EDT
Revenue
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|
| Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 |
|---|
North American Pharmaceutical Revenue | 336.65B | 304.51B | | | | | | | | |
North American Pharmaceutical Revenue Growth | 10.56% | 16.50% | | | | | | | | |
Oncology & Multispecialty Revenue | 48.42B | 36.86B | | | | | | | | |
Oncology & Multispecialty Revenue Growth | 31.36% | 20.90% | | | | | | | | |
Prescription Technology Solutions Revenue | 5.81B | 5.22B | | | | | | | | |
Prescription Technology Solutions Revenue Growth | 11.29% | 9.37% | | | | | | | | |
Medical Surgical Solutions Revenue | 11.51B | 11.38B | | | | | | | | |
Medical Surgical Solutions Revenue Growth | 1.12% | 0.63% | | | | | | | | |
| 1.04B | 1.09B | | | | | | | | |
Other Segment Revenue Growth | -3.96% | 7.00% | | | | | | | | |
| 403.43B | 359.05B | | | | | | | | |
| 12.36% | 16.22% | | | | | | | | |
EBIT
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|
| Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 |
|---|
North American Pharmaceutical Operating Profit | 3.66B | 2.95B | | | | | | | | |
North American Pharmaceutical Operating Profit Growth | 24.21% | 25.96% | | | | | | | | |
Oncology & Multispecialty Operating Profit | 1.15B | 767.00M | | | | | | | | |
Oncology & Multispecialty Operating Profit Growth | 49.80% | 8.49% | | | | | | | | |
Prescription Technology Solutions Operating Profit | 1.04B | 875.00M | | | | | | | | |
Prescription Technology Solutions Operating Profit Growth | 19.31% | 4.79% | | | | | | | | |
Medical Surgical Solutions Operating Profit | 938.00M | 779.00M | | | | | | | | |
Medical Surgical Solutions Operating Profit Growth | 20.41% | -18.43% | | | | | | | | |
Other Segment Operating Profit | 590.00M | 54.00M | | | | | | | | |
Other Segment Operating Profit Growth | 992.59% | -5.26% | | | | | | | | |
| -1.17B | -998.00M | | | | | | | | |
| 6.21B | 4.42B | | | | | | | | |
Operating Income (Total) Growth | 40.48% | 13.12% | | | | | | | | |
Capital Expenditures
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|
| Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 |
|---|
US Pharmaceutical Capital Expenditures | 241.00M | | | | | | | | |
US Pharmaceutical Capital Expenditures Growth | 24.87% | | | | | | | | |
Prescription Technology Solutions Capital Expenditures | 11.00M | | | | | | | | |
Prescription Technology Solutions Capital Expenditures Growth | -64.52% | | | | | | | | |
Medical Surgical Solutions Capital Expenditures | 163.00M | | | | | | | | |
Medical Surgical Solutions Capital Expenditures Growth | 2.52% | | | | | | | | |
International Capital Expenditures | 107.00M | | | | | | | | |
International Capital Expenditures Growth | 42.67% | | | | | | | | |
Updated May 7, 2026. Data Source:
Fiscal.ai.
